Suppression Of Lncrna Malat1 Reduces Lps- Or Il-17a-Induced Inflammatory Response In Human Middle Ear Epithelial Cells Via The Nf-Kappa B Signaling Pathway

Otitis media (OM) is a common inflammatory disease of the middle ear cavity and mainly occurs in children. As a critical regulator of inflammation response, the nuclear factor kappa B (NF-kappa B) pathway has been found to play an essential role in the pathogenesis of various human diseases. The aim of this study was to explore the potential mechanism under the inflammatory response of human middle ear epithelial cells (HMEECs). We established in vitro models of OM by treating HMEECs with lipopolysaccharide (LPS) or interleukin 17A (IL-17A). Enzyme-linked immunosorbent assay and western blot analysis were used to measure the inflammatory response of HMEECs under LPS or IL-17A stimulation. The results revealed that the concentrations of proinflammatory cytokines (p<0.001) and protein levels of mucin (MUC) (for MUC5AC, p=0.002, p=0.004; for MUC8, p=0.004, p<0.001) were significantly elevated by LPS or IL-17A stimulation in HMEECs. Moreover, we found that LPS or IL-17A treatment promoted the phosphorylation of I kappa B alpha (for p-I kappa B alpha, p=0.018, p=0.002; for I kappa B alpha, p=0.238, p=0.057) and the translocation of p65 from cytoplasm to nucleus in HMEECs (for nucleus p65, p=0.01; for cytoplasm p65, p<0.001). In addition, RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs (p<0.001). Western blot analysis and immunofluorescence staining assay revealed that that MALAT1 knockdown significantly suppressed the activation of the NF-kappa B pathway by reducing phosphorylated I kappa B alpha levels and inhibiting the nuclear translocation of p65 (p<0.001) in LPS- or IL-17A-stimulated HMEECs (for p-I kappa B alpha, p<0.001; for I kappa B alpha, p=0.242, p=0.647). Silence of MALAT1 decreased the proinflammatory cytokine production and MUC protein levels (p<0.001). Furthermore, rescue assays revealed that the increase of proinflammatory cytokine production (for TNF-alpha, p=0.002, p=0.015; for IL-1 beta, p<0.001, p=0.006; for IL-6, p=0.002, p<0.001) and MUC protein levels (for MUC5AC, p=0.001, p<0.001; for MUC8, p<0.001, p=0.001) induced by MALAT1 overexpression was neutralized by 4-N-[2-(4-phenoxyphenyl) ethyl] quinazoline-4, 6-diamine (QNZ) treatment in LPS- or IL-17A-stimulated HMEECs. In conclusion, MALAT1 promotes inflammatory response in LPS- or IL-17A- stimulated HMEECs via the NF-kappa B signaling pathway, which may provide a potential novel insight for the treatment of OM.